Moreover, coexpression of FOXM1, survivin, and nuclear XIAP was associated with poor outcomes of women with stage III breast cancer with significantly reduced 5- and 10-year survival rates versus women with tumors without these features. This evidence concerns the gene FOXM1 and breast cancer.